ODTX · Odyssey Therapeutics, Inc.
$24.67
+0.42 (+1.73%)
At close · Aug 20
Market Cap
$1.17B
Shares
48.06M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.67
Open$24.40
Day$23.07–24.77
Available close range$15.56–24.67
Avg vol 30d213K
Short int2.3M · 4.7% float · 9.7d
Short vol81%
DataMay 2026–Aug 2026
Filing10-Q · Aug 6
The closing range uses available history since May 8, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+32%
above
RSI (14)
71
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+58 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.73% of float · ▲ +13.9% MoM · 9.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
58 holders — 13F breadth
Squeeze score
95
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−18%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+32%
Bullish
RSI (14)
71
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+58 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.73% of float · ▲ +13.9% MoM · 9.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
58 holders — 13F breadth
Price context
position in its available closing range
Range low $16
Now $25 · 100%
Range high $25
vs 50-day avg +32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $433.1M | As of June 30, 2026 | — |
| Additional shares purchased through partial exercise of the underwriters’ option | 600,000 | first quarter 2026 | — |
| Common stock sold in the concurrent private placement | 1,388,889 | first quarter 2026 | — |
| Common stock sold in the initial public offering | 15,500,000 | first quarter 2026 | — |
| Gross proceeds | $314.8M | first quarter 2026 | — |
| Initial public offering price | $18 | first quarter 2026 | — |
| Net proceeds from the initial public offering and concurrent private placement | $288.7M | March 31, 2026 | — |
| Patients achieving clinical remission | 27% | 12 weeks of treatment | — |
| Patients achieving clinical response | 61% | 12 weeks of treatment | — |
| Patients completing treatment and eligible for efficacy analysis | 49 | 12 weeks of treatment | — |
| Pro-forma cash position | $464.4M | March 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ODTX
this stock
Odyssey Therapeutics, Inc.
|
$1.17B | — | — | — | 4.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ODTX | +19.1% | +39.6% | — | +30.3% | — |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +21.0% | +36.3% | — | +28.2% | — |